Musculoskeletal Disorders

MD IQ

News from the FDA/CDC

FDA approves first tocilizumab biosimilar

Tocilizumab-bavi (Tofidence) will offer a lower-cost option for patients with autoimmune conditions, the drug manufacturer, Biogen, stated.

Letters from Maine

Pain mismanagement by the numbers

Pain is a complex, multifaceted phenomenon. Distilling a person’s pain experience to a single number doesn’t make sense, nor does reflexly...

Feature

Humira biosimilars: Five things to know

The launch of eight adalimumab biosimilars so far in 2023 ended Humira’s 20-year monopoly, but it’s not clear yet if these discounted drugs will...

Pages